Genelux Corporation Announces $18 Million Private Placement
June 12, 2023 07:00 ET
|
Genelux Corporation
WESTLAKE VILLAGE, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement for 900,000 shares...
Myriad Genetics Adds Folate Receptor Alpha to Precise™ Oncology Solutions Portfolio to Expand Treatment Options for Women Living with Ovarian Cancer
May 24, 2023 16:05 ET
|
Myriad Genetics, Inc.
Biomarker offers another companion diagnostic option to establish eligibility for FDA-approved drug ELAHERE® SALT LAKE CITY, May 24, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a...
AIM ImmunoTech Reports First Quarter Financial Results and Provides Pipeline Update
May 15, 2023 08:45 ET
|
AIM ImmunoTech Inc.
– Continued execution across pipeline positions AIM to achieve multiple clinical and regulatory value-driving milestones throughout 2023– Lead clinical program, Phase 2 locally advance pancreatic...
Genelux Corporation Announces $33 Million Private Placement
May 15, 2023 07:00 ET
|
Genelux Corporation
WESTLAKE VILLAGE, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement of 1,665,247 shares...
Community Oncology Services Global Market Report 2023: Government Investments in Oncology Bolsters $132.5 Billion Industry
April 07, 2023 04:38 ET
|
Research and Markets
Dublin, April 07, 2023 (GLOBE NEWSWIRE) -- The "Community Oncology Services Global Market Opportunities And Strategies To 2032" report has been added to ResearchAndMarkets.com's offering.The...
AIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and Webcast
March 27, 2023 09:05 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., March 27, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
AIM ImmunoTech Issues Letter to Stockholders
March 06, 2023 08:45 ET
|
AIM ImmunoTech Inc.
Year marked by noteworthy operational execution and clinical development progress across pipeline Company reiterates commitment to continued communication and activity with the investment and...
IMUNON and Break Through Cancer Commence Enrollment in a Phase 1/2 Clinical Study of IMNN-001 in Combination with Avastin in Advanced Ovarian Cancer
February 27, 2023 08:30 ET
|
Imunon, Inc.
The study will be partially funded by Break Through Cancer through the Ovarian Minimal Residual Disease Team Lab LAWRENCEVILLE, NJ and CAMBRIDGE, MA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- IMUNON,...
Zai Lab to Present Two New Phase 3 Analyses for Niraparib in Ovarian Cancer at the 2023 ESMO Gynaecological Cancers Congress
February 22, 2023 16:30 ET
|
Zai Lab Limited
SHANGHAI, China and CAMBRIDGE, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) will present two oral presentations highlighting the ad hoc interim overall...
Chemotherapy At Home Services Market Research Report 2022: Strategic Partnerships and Collaborations Fueling Market Growth
February 03, 2023 07:33 ET
|
Research and Markets
Dublin, Feb. 03, 2023 (GLOBE NEWSWIRE) -- The "Chemotherapy At Home Services Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Product (Chemotherapy...